

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Carbamazepine 100 mg Chewable Tablet (DIN 02231542) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective October 8, 2015**.

CARBAMAZEPINE

100 MG ORAL CHEWABLE TABLET

00002231542	PMS-CARBAMAZEPINE	PMS	\$ 0.0380
00000369810	TEGRETOL	NOV	\$ 0.1657

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Carbamazepine 200 mg Chewable Tablet (DIN 02231540) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective October 8, 2015**.

CARBAMAZEPINE

200 MG ORAL CHEWABLE TABLET

00002231540	PMS-CARBAMAZEPINE	PMS	\$ 0.0749
00000665088	TEGRETOL	NOV	\$ 0.3271

Alberta Blue Cross has been advised by Ratiopharm that the shortage of Ratio-Lenoltec No.3 Tablet (DIN 00653276) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective October 8, 2015**.

CODEINE PHOSPHATE/ ACETAMINOPHEN/ CAFFEINE

30 MG / 300 MG / 15 MG ORAL TABLET

00000653276	RATIO-LENOLTEC NO.3	RPH	\$ 0.0845
00002163926	TYLENOL NO. 3	JAI	\$ 0.0954

continued on next page ...

... continued from previous page

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Oxycodone 10 mg Tablet (DIN 02319985) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, first tier pricing will be reapplied to the following grouping **effective October 8, 2015**.

OXYCODONE

10 MG ORAL TABLET

00002319985	PMS-OXYCODONE	PMS	\$ 0.1896
00000443948	SUPEUDOL	SDZ	\$ 0.2283
00002240131	OXY-IR	PUR	\$ 0.3895

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Cimetidine 400 mg Tablet (DIN 02227452) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective October 9, 2015**.

CIMETIDINE

400 MG ORAL TABLET

00002227452	MYLAN-CIMETIDINE	MYP	\$ 0.1350
00000600059	APO-CIMETIDINE	APX	\$ 0.2930

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Risperidone ODT 0.5 mg Orally Disintegrating Tablet (DIN 02413485) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective October 12, 2015**.

RISPERIDONE

0.5 MG ORAL DISINTEGRATING TABLET

00002413485	MYLAN-RISPERIDONE ODT	MYP	\$ 0.5588
00002247704	RISPERDAL M-TAB	JAI	\$ 0.7823

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)
FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)
